Altru Hospital is a medicare approved dialysis facility center in Grand Forks, North Dakota and it has 13 dialysis stations. It is located in Grand Forks county at 1200 S Columbia Rd, Grand Forks, ND, 58201. You can reach out to the office of Altru Hospital at (701) 780-5870. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Altru Hospital has the following ownership type - Non-Profit. It was first certified by medicare in August, 1977. The medicare id for this facility is 350019 and it accepts patients under medicare ESRD program.
| Name | Altru Hospital |
|---|---|
| Location | 1200 S Columbia Rd, Grand Forks, North Dakota |
| No. of Dialysis Stations | 13 |
| Medicare ID | 350019 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 1200 S Columbia Rd, Grand Forks, North Dakota, 58201 | |
| (701) 780-5870 | |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
| NPI Number | 1033208509 |
| Organization Name | Altru Health System - Renal Dialysis - Grand Forks |
| Doing Business As | Altru Health System |
| Address | 1200 S Columbia Rd Grand Forks, North Dakota, 58201 |
| Phone Number | (701) 780-5000 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 62 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 8 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 67 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 584 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 33 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 283 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 89 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Altru Hospital with elevated calcium levels.
| Patients with hypercalcemia | 109 |
| Hypercalcemia patient months | 978 |
| Patients with Serumphosphor | 126 |
| Patients with Serumphosphor less than 3.5 mg/dL | 12 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 34 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
| Patients with Serumphosphor greater than 7 mg/dL | 5 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 94 |
| Patient months included in arterial venous fistula and catheter summaries | 639 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 83 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 105 |
| Hospitalization Rate in facility | 137.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 239.8 |
| Hospitalization Rate: Lower Confidence Limit | 85.5 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Altru Hospital were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 25 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.2 |
| Readmission Rate: Lower Confidence Limit | 17.9 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Altru Hospital get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.05 (As Expected) |
| SIR: Upper Confidence Limit | 2.07 |
| SIR: Lower Confidence Limit | .46 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Altru Hospital's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 94 |
| Transfusion Rate in facility | 38 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 78.2 |
| Transfusion Rate: Lower Confidence Limit | 20.2 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Altru Hospital lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 446 |
| Mortality Rate in facility | 17 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.4 |
| Mortality Rate: Lower Confidence Limit | 13.4 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago
THE Kidney Institute Of North Dakota Location: 1451 - 44th Ave S, Grand Forks, North Dakota, 58201 Phone: (701) 795-1300 |
Aurora Dialysis Llc Location: 1451 - 44th Ave S, Grand Forks, North Dakota, 58201 Phone: (701) 757-5700 |
News Archive
Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.
dbMotion, a provider of health interoperability solutions, announced its participation at HIMSS 2010, March 1-4 in Atlanta, Ga., both as an exhibitor (Booth 6023) and as a featured contributor to the Interoperability Showcase—demonstrating how providers can achieve meaningful data-sharing across a range of healthcare settings. Participation in the Interoperability Showcase comes on the heels of dbMotion's successful completion of interoperability testing at the 11th Annual IHE North American Connectathon in Chicago.
Protein systems, such as Ras, make up the complex signaling pathways that control whether a cell divides or, in some cases, becomes cancerous and metastasizes into other regions of the body. For example, 98 percent of pancreatic cancers show Ras protein mutations.
Taro Pharmaceutical Industries Ltd.("Taro" or the "Company") today announced the preliminary results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired at 12:00 midnight, New York City time, on Monday, December 23, 2013.
› Verified 2 days ago